Hanson & Doremus Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hanson & Doremus Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-200	Closed	-$25K	–	412
2020 Q2	$25K	Hold	200	–	–	0.01%	307
2020 Q1	$17K	Hold	200	–	–	0.01%	353
2019 Q4	$17K	Hold	200	–	–	﹤0.01%	383
2019 Q3	$13K	Hold	200	–	–	﹤0.01%	392
2019 Q2	$17K	Hold	200	–	–	0.01%	384
2019 Q1	$18K	Hold	200	–	–	0.01%	362
2018 Q4	$17K	Hold	200	–	–	0.01%	348
2018 Q3	$19K	Hold	200	–	–	0.01%	362
2018 Q2	$19K	Hold	200	–	–	0.01%	384
2018 Q1	$16K	Hold	200	–	–	0.01%	410
2017 Q4	$18K	Hold	200	–	–	0.01%	395
2017 Q3	$19K	Hold	200	–	–	0.01%	377
2017 Q2	$18K	Hold	200	–	–	0.01%	379
2017 Q1	$18K	Hold	200	–	–	0.01%	364
2016 Q4	$16.6K	Hold	200	–	–	0.01%	344
2016 Q3	$19K	Hold	200	–	–	0.01%	322
2016 Q2	$16K	Hold	200	–	–	0.01%	329
2016 Q1	$16K	Hold	200	–	–	0.01%	337
2015 Q4	$21K	Hold	200	–	–	0.01%	328
2015 Q3	$21K	Hold	200	–	–	0.01%	315
2015 Q2	$27K	Hold	200	–	–	0.01%	304
2015 Q1	$25K	Hold	200	–	–	0.01%	312
2014 Q4	$18K	Hold	200	–	–	0.01%	341
2014 Q3	$14K	Hold	200	–	–	0.01%	343
2014 Q2	$12K	Hold	200	–	–	0.01%	348
2014 Q1	$14K	Hold	200	–	–	0.01%	334
2013 Q4	$14K	Hold	200	–	–	0.01%	334
2013 Q3	$14K	Hold	200	–	–	0.01%	322
2013 Q2	$11K	Buy	+200	New	+$12.5K	0.01%	311

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hanson & Doremus Investment Management's BMRN Position: Q3 2020 in Review

Hanson & Doremus Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 200 shares — an estimated $25K sold.

Hanson & Doremus Investment Management first reported a position in BMRN in Q2 2013 and held it in 29 quarters. The position peaked at $27K in Q2 2015. 497 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

Hanson & Doremus Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Hanson & Doremus Investment Management sold 200 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $25K.
Hanson & Doremus Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 29 quarters.
Hanson & Doremus Investment Management's BioMarin Pharmaceuticals position peaked at $27K in Q2 2015.
497 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Hanson & Doremus Investment Management's 13F filing for Q3 2020, filed 19 Oct 2020.